Inhibition of the PI3K pathway using small molecules targeting PI3K, mTOR, or AKT was recently investigated but has not yielded satisfactory results in CRC patients with PI3K alterations [46]. This evidence concerns the gene PIK3CA and colorectal carcinoma.